Skip to main content
Clinical Trials/NCT06113315
NCT06113315
Enrolling By Invitation
Not Applicable

An Observational Study of Sarcoma Patients Treated With Immunotherapy at Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center7 sites in 1 country250 target enrollmentOctober 27, 2023
ConditionsSarcoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcoma
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
250
Locations
7
Primary Endpoint
prospectively collect and store blood
Status
Enrolling By Invitation
Last Updated
6 months ago

Overview

Brief Summary

The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.

Registry
clinicaltrials.gov
Start Date
October 27, 2023
End Date
October 1, 2028
Last Updated
6 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist.
  • Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll

Exclusion Criteria

  • Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB or ACT initiation), during, and after ICB or ACT treatment

Outcomes

Primary Outcomes

prospectively collect and store blood

Time Frame: up to 5 years

of sarcoma patients treated with ICB or ACT

Study Sites (7)

Loading locations...

Similar Trials